Sigma-Aldrich has signed a series of agreements that expands its position in the areas of RNA Interference (RNAi), gene expression and cell-based assays. Sigma-Aldrich and Genospectra, a developer of products to support systems biology and drug discovery efforts, have signed several agreements in which Sigma-Aldrich acquires a minority equity stake in Genospectra and is granted access to various Genospectra technologies. Under the terms of the agreement, Sigma-Aldrich gained access to the Q...